IDH1 and glioma: The latest 2021 WHO classification of CNS tumor relies heavily on isocitrate dehydrogenase (IDH) mutation status given its considerable diagnostic and predictive values: for example, the presence of IDH mutation in gliomas is linked to more favorable prognosis.